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In March this year the ELITE Study (Evaluation of release is stimulated causing sodium and water Losartan in the Elderly) was published in The Lanretention.
1 Strenuous efforts have therefore been cet. 7 This was a randomised trial of losartan (50 mg) made at finding ways in modifying various compoonce daily compared with captopril 50 mg three nents of the renin-angiotensin system that have been times daily in the treatment of heart failure in implicated in the pathogenesis of heart failure.
patients over 65 years of age. The findings of this Exactly 10 years ago, the CONSENSUS Trial trail are of great interest as over the 400 days of the Study Group published their landmark paper on the study, the 352 patients receiving losartan had a 46% use of enalapril in severe heart failure.
2 This and lower risk of death than the 370 patients in the capseveral other subsequent trials have shown convinctopril group (P = 0.035). Small numbers make the ingly that angiotensin-converting enzyme (ACE) further interpretation of the trial results (particularly inhibitors reduce morbidity and mortality in event rates) a little problematic. However, losartan patients with heart failure.
3,4 Furthermore there is was associated with a 26% reduction in hospital now evidence that patients who have left ventricular admissions for all causes and strangely a 35% systolic dysfunction following myocardial infarcreduction in non-cardiovascular deaths (five vs eight tion also significantly, benefit from the use of ACE patients), a 64% reduction in sudden death (five vs inhibitors. 5 14 patients) and a 76% reduction in myocardial The development of the angiotensin II receptor infarction (one vs four patients). Admission to hosantagonist class of drugs and the subsequent launch pital for heart failure and progressive heart failure of its first member, losartan, represented an were however, not different between the two drug important event in the world of antihypertensive classes. The improvement in symptoms was similar therapy.
6 Whilst the angiotensin II receptor antagonin both groups as assessed by the New York Heart ists and the ACE inhibitors have similar modes of Association (NYHA) Functional Class Criteria. action in that they block the renin-angiotensin sysNotably, non-fatal adverse events and side effects tem, there are also notable differences. For example, were significantly lower in the losartan patients the ACE inhibitors prevent the breakdown of the compared with the captopril patients (P = 0.02). vasodilating hormone, bradykinin, but do not totally
The ELITE Trial does clearly validate the use of block the generation of angiotensin II. By contrast, losartan in the treatment of heart failure and in fact losartan does avidly block the AT1 receptor for angimany cardiologists have already been using it otensin II but lacks any significant effect on the despite the lack of trial data. The ELITE Study was kinin system. conducted in patients with relatively mild heart failOnly long term outcome trials can provide inforure and the trialists state that a further trial 'evaluatmation on whether the AT1 receptor antagonists are ing effects of losartan and captopril on mortality and better than, the same as, or possibly worse than the morbidity in a large number of patients with heart failure is in progress' (ELITE 2). All long term outcome trials tend to pose as many questions as they answer and this is certainly true Correspondence: Professor DG Beevers.
of ELITE. One must question why the trialists chose patients with left ventricular hypertrophy has recently completed the recruitment phase (the Losto use captopril rather than enalapril. The stated reaartan Intervention For Endpoint or LIFE trial). There son was because captopril 'may have fewer renal are also other ongoing trials of angiotensin II recepside effects than longer acting ACE inhibitors', a tor antagonists in the management of heart failure. statement based upon an early comparison of captoFor example, one study (VALHeFT) is comparing pril with enalapril in severe heart failure. 8 However, the effects of valsartan or placebo in addition to there must also be a little speculation that this standard therapy in managing patients with moderdecision might have been partly influenced by comate to severe (NYHA II to IV) heart failure. Another mercial considerations. At the dose employed in the pilot study (RESOLVD) aims to compare ACE inhibi-ELITE trial, the captopril regimen was twice as tor therapy and additive angiotensin II antagonism expensive as losartan and there was also the incon-(with candesartan) in severe heart failure (NYHA III venience of thrice daily dosing. Enalapril given once and IV). However, it is unlikely that any results will daily in a dose of 20 mg would have been somewhat be available from these trials until well past the cheaper than losartan and equally convenient.
year 2000. The other questions posed by this trial, however,
In the interim, however, we can be reasonably are more intriguing. Why was losartan better than reassured that the angiotensin II receptor antagonists captopril in terms of preventing sudden death, acute represent not only a new class of antihypertensive myocardial infarction and non-cardiac death? Does agents, but are safe with extra potential benefits in this reflect other properties of the losartan molecule the treatment of heart failure. that have not been previously recognised? One could suggest that the reduction in sudden death References might be due to an anti-arrhythmic effect and the reduction of myocardial infarction might be due to
